Simon Fraser University researchers are using a new approach to brain imaging that could improve how drugs are prescribed to ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

Texas plans to spend $50 million on research examining the effects of a psychedelic drug called Ibogaine on behavioral health ...

The U.S. Food and Drug Administration said on Tuesday that it is investigating reports of two deaths due to acute liver ...

A new gene therapy delivery device could let hospital pharmacies make personalized nanomedicines to order. This democratized ...

Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

Advocates for veterans are championing Assembly Bill 1103, which would fast-track the approval of academic studies on ...

U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. says his agency is “absolutely committed” to ...

Only five days after FDA approval of Yutrepia, Liquidia announced its first commercial shipment of the therapy, making prescriptions available to patients at specialty pharmacies. “We have moved with ...

The ouster of the FDA's chief regulator of cell and gene therapies came immediately after a disagreement with her boss over a ...

enGene Holdings shares were up 7% to $3.25 after the company said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to detalimogene voraplasmid.

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...